CTS — CTS Corporation

CTS Corporation Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $145 million, a 7% increase year-over-year and a 4% sequential increase.
• Gross Margin: Record 41.5%, up 270 basis points from Q2 2025.
• Adjusted EBITDA Margin: 25.4%, an improvement of approximately 240 basis points year-over-year.
• Adjusted Diluted EPS: $0.74, up from $0.57 in Q2 2025, benefiting from $0.07 in favorable one-time items.
• Cash Flow: Operating cash flow of $33 million; free cash flow of approximately $29 million.
• Book-to-Bill Ratio: 1.1 overall, with diversified markets at 1.17.

2. Strategic Updates and Business Highlights

• Leadership Transition: Prateek Trivedi took over as CEO, emphasizing the continuation of the Evolution 30 strategy and diversification focus.
• Diversified End Markets: Sales increased by 15% year-over-year, now representing 59% of total sales.
• Medical Market Growth: Revenue surged 45% year-over-year, driven by strong demand in diagnostics and therapeutics.
• Transportation Segment: Despite a 2% decline in sales, significant new business awards totaling $163 million were secured, including a $100 million contract with a North American OEM.
• Aerospace and Defense: Sales decreased 15% year-over-year but showed signs of recovery with a growing backlog and new customer additions.

3. Forward Guidance and Outlook

• Full Year 2026 Guidance: Revenue is now expected in the range of $565 million to $585 million, with adjusted diluted EPS projected between $2.55 and $2.70.
• Market Outlook: Continued solid demand in diversified markets, particularly in medical and industrial sectors. Aerospace and defense expected to strengthen in the second half due to improved government funding.

4. Challenges and Points of Concern

• Transportation Market Risks: Global light vehicle production is forecasted to be flat to slightly down due to geopolitical tensions and tariff uncertainties.
• Cost Pressures: Ongoing discussions regarding pricing adjustments due to inflationary pressures and tariffs, with potential impacts on margins.
• Aerospace and Defense Sales Decline: Notable year-over-year drop, although a recovery is anticipated in the latter half of the year.

5. Notable Q&A Insights

• CEO Transition: Prateek Trivedi highlighted his experience and focus on accelerating growth in diversified markets while stabilizing transportation.
• R&D Expenses: CFO Ashish Agrawal indicated that R&D expenses are expected to normalize, but customer reimbursements may still occur.
• Medical Segment Margins: It was confirmed that the medical sector generally has higher gross margins compared to other diversified markets.
• Transportation Book-to-Bill: Clarified that the transportation segment's book-to-bill ratio is typically close to 1.0 due to short cycle orders.
• Commercial Vehicle Market Outlook: Modest growth is anticipated in the second half, driven by rising freight rates and prebuy activity related to emissions regulations.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and challenges faced by CTS Corporation as discussed in the Q2 2026 earnings call.